Cancers 2010, 2(1), 1-19; doi:10.3390/cancers2010001
Review

Novel Combinations for the Treatment of Metastatic Breast Cancer

email
Received: 17 November 2009; in revised form: 29 December 2009 / Accepted: 5 January 2010 / Published: 14 January 2010
(This article belongs to the Special Issue Breast Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.
Keywords: metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival
PDF Full-text Download PDF Full-Text [526 KB, uploaded 14 January 2010 13:21 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Vahdat, L.T. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers 2010, 2, 1-19.

AMA Style

Vahdat LT. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers. 2010; 2(1):1-19.

Chicago/Turabian Style

Vahdat, Linda T. 2010. "Novel Combinations for the Treatment of Metastatic Breast Cancer." Cancers 2, no. 1: 1-19.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert